German Antitrust Clears Esperion Merger; Shareholder Vote Set for July 8
ESPR has more than doubled off its 52-week low of $0.949.
Summary
Esperion Therapeutics has received clearance from the German antitrust authority for its planned acquisition by Essence Parent, removing a key regulatory hurdle. This follows the definitive merger agreement announced on May 1st for $3.16 per share in cash plus CVRs. The special meeting for stockholders to vote on the merger is confirmed for July 8, 2026, a date previously disclosed in the definitive proxy statement filed on June 8th. This regulatory approval significantly increases the likelihood of the acquisition closing. Investors should watch the stockholder vote on July 8th.
At the time of this announcement, ESPR was trading at $3.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $808.3M. The 52-week trading range was $0.95 to $4.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.